NZ789041A - The use of inhibitors of bruton’s tyrosine kinase (btk) - Google Patents

The use of inhibitors of bruton’s tyrosine kinase (btk)

Info

Publication number
NZ789041A
NZ789041A NZ789041A NZ78904111A NZ789041A NZ 789041 A NZ789041 A NZ 789041A NZ 789041 A NZ789041 A NZ 789041A NZ 78904111 A NZ78904111 A NZ 78904111A NZ 789041 A NZ789041 A NZ 789041A
Authority
NZ
New Zealand
Prior art keywords
bruton
btk
tyrosine kinase
inhibitors
macroglobulinemia
Prior art date
Application number
NZ789041A
Other languages
English (en)
Inventor
Joseph Buggy
Laurence Elias
Gwen Fyfe
Eric Hedrick
David Loury
Tarak Mody
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45067334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ789041(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of NZ789041A publication Critical patent/NZ789041A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ789041A 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk) NZ789041A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35113010P 2010-06-03 2010-06-03
US35165510P 2010-06-04 2010-06-04
US35176210P 2010-06-04 2010-06-04
US35179310P 2010-06-04 2010-06-04
US41976410P 2010-12-03 2010-12-03
US201161472138P 2011-04-05 2011-04-05
NZ772688A NZ772688A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)

Publications (1)

Publication Number Publication Date
NZ789041A true NZ789041A (en) 2023-09-29

Family

ID=45067334

Family Applications (7)

Application Number Title Priority Date Filing Date
NZ702485A NZ702485A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ772688A NZ772688A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ604040A NZ604040A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ73604811A NZ736048A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ753024A NZ753024A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ717373A NZ717373A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ789041A NZ789041A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)

Family Applications Before (6)

Application Number Title Priority Date Filing Date
NZ702485A NZ702485A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ772688A NZ772688A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ604040A NZ604040A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ73604811A NZ736048A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ753024A NZ753024A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ717373A NZ717373A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)

Country Status (18)

Country Link
US (24) US20120087915A1 (enExample)
EP (1) EP2575818A4 (enExample)
JP (8) JP5841998B2 (enExample)
KR (1) KR101580714B1 (enExample)
CN (2) CN103153311A (enExample)
AU (1) AU2011261185A1 (enExample)
BR (1) BR112012030625A2 (enExample)
CA (7) CA3007787C (enExample)
CL (1) CL2012003381A1 (enExample)
EA (2) EA201890869A3 (enExample)
IL (3) IL300955A (enExample)
MX (4) MX342405B (enExample)
MY (1) MY191929A (enExample)
NZ (7) NZ702485A (enExample)
PH (3) PH12012502356A1 (enExample)
SG (2) SG10201809111XA (enExample)
WO (1) WO2011153514A2 (enExample)
ZA (1) ZA201209381B (enExample)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101516339B (zh) * 2006-08-16 2012-06-13 诺瓦提斯公司 制备高度结晶的治疗化合物的固体分散体的方法
ES2616789T3 (es) 2006-09-22 2017-06-14 Pharmacyclics, Inc. Inhibidores de tirosina cinasa de Bruton
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
SG183044A1 (en) 2007-07-16 2012-08-30 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN104926815B (zh) 2008-01-04 2017-11-03 英特利凯恩有限责任公司 某些化学实体、组合物和方法
US9669057B2 (en) 2008-04-25 2017-06-06 Duke University Regulatory B cells and their uses
US20090301928A1 (en) * 2008-06-05 2009-12-10 United Comb & Novelty Corporation Packaging For Lipped Containers
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US10131875B2 (en) 2010-08-04 2018-11-20 Duke University Regulatory B cells and their uses
RU2013109393A (ru) 2010-08-10 2014-09-20 Сэлджин Авиаломикс Ресеарч, Инк. Безилатная соль ингибитора втк
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
TWI545115B (zh) 2010-11-01 2016-08-11 阿維拉製藥公司 雜環化合物及其用途
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
CN103826629A (zh) * 2011-03-11 2014-05-28 吉里德卡利斯托加公司 恶性血液病的组合治疗
NZ618062A (en) * 2011-04-28 2016-04-29 Sloan Kettering Inst Cancer Hsp90 combination therapy
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
CN103534258B (zh) 2011-05-17 2016-09-14 普林斯匹亚生物制药公司 酪氨酸激酶抑制剂
CN103857396A (zh) 2011-07-13 2014-06-11 药品循环公司 布鲁顿酪氨酸激酶抑制剂
SI3689878T1 (sl) 2011-07-19 2021-12-31 Merck Sharp & Dohme B.V. 4-imidazopiridazin-1-il-benzamidi in 4-imidazotriazin-1-il-benzamidi kot Btk-zaviralci
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
JP6506555B2 (ja) * 2011-10-19 2019-04-24 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用
AR088570A1 (es) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
PT2657233E (pt) * 2012-01-19 2014-10-24 Taiho Pharmaceutical Co Ltd Composto de alcinil-benzeno substituído nas posições 3 e 5 e um seu sal
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
HK1206624A1 (en) * 2012-04-11 2016-01-15 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
KR20230170108A (ko) 2012-06-04 2023-12-18 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014004707A1 (en) * 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
LT3181567T (lt) 2012-09-10 2019-07-25 Principia Biopharma Inc. Pirazolpirimidino junginiai kaip kinazės slopikliai
HRP20181367T4 (hr) 2012-11-01 2021-11-26 Infinity Pharmaceuticals, Inc. Liječenje raka korištenjem modulatora izoforme pi3 kinaze
CA2890111A1 (en) * 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
BR112015011171A2 (pt) * 2012-11-15 2017-07-11 Pharmacyclics Inc compostos de pirrolopirimidina como inibidores da quinase
EP2922827A4 (en) * 2012-11-20 2016-06-08 Celgene Avilomics Res Inc METHOD FOR THE TREATMENT OF A DISEASE OR DISEASE RELATED TO BRUTON TYROSINE KINASE
TW201427666A (zh) * 2012-11-20 2014-07-16 Celgene Avilomics Res Inc 治療和布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶相關之疾病或失調的方法
EP2922546A4 (en) * 2012-11-20 2016-06-08 Celgene Avilomics Res Inc METHOD FOR THE TREATMENT OF A DISEASE OR DISEASE RELATED TO BRUTON TYROSINE KINASE
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
EP2936157A1 (en) * 2012-12-21 2015-10-28 Servicio Andaluz De Salud Expression of beta2-microglobulin as a prognostic marker for tumour immune escape and resistance to cancer immunotherapy and a diagnostic biomarker for patient selection for specific gene therapy
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2948458B1 (en) 2013-01-23 2019-05-01 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014113932A1 (en) * 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
EA201591051A1 (ru) 2013-02-08 2016-06-30 Селджен Авиломикс Рисерч, Инк. Ингибиторы erk и варианты их применения
DK2970205T3 (da) 2013-03-14 2019-07-29 Tolero Pharmaceuticals Inc JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
JP2016512549A (ja) * 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
MX369503B (es) * 2013-04-08 2019-11-11 Pharmacyclics Llc Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CA2902686C (en) 2013-04-25 2017-01-24 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
EP3003309B1 (en) * 2013-05-30 2020-09-09 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
JP6084292B2 (ja) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
DK3023100T3 (da) * 2013-07-18 2019-05-27 Taiho Pharmaceutical Co Ltd Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors
CA2920534A1 (en) 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
EA201690618A1 (ru) 2013-09-30 2016-09-30 Фармасайкликс Элэлси Ингибиторы тирозинкиназы брутона
US20150105409A1 (en) * 2013-10-10 2015-04-16 Acetylon Pharmaceticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating nonhodgkin's lymphoma
JP2016538270A (ja) 2013-10-25 2016-12-08 ファーマサイクリックス エルエルシー 移植片対宿主病を処置し予防する方法
KR102357699B1 (ko) * 2013-11-06 2022-02-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 발현 프로파일링에 의한 림프종 유형의 하위유형 분류 방법
TWI743019B (zh) * 2013-12-02 2021-10-21 美商製藥公司 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
KR20160093062A (ko) * 2013-12-05 2016-08-05 아세르타 파마. 비.브이. Pi3k 억제제 및 btk 억제제의 치료적 조합
WO2015095099A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015095102A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
WO2015110923A2 (en) * 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
KR20220027271A (ko) 2014-02-21 2022-03-07 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
US9949971B2 (en) 2014-06-17 2018-04-24 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
WO2016019233A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
BR112017001677A2 (pt) * 2014-08-01 2018-07-17 Pharmacyclics Llc biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk
CA2955747A1 (en) 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
BR112017002232A2 (pt) 2014-08-08 2018-07-24 Janssen Pharmaceutica Nv combinações de inibidor de tirosina quinase de bruton e usos das mesmas
PT3179991T (pt) 2014-08-11 2021-11-26 Acerta Pharma Bv Combinações terapêuticas de um inibidor de btk e um inibidor de bcl-2
TW201609099A (zh) * 2014-08-11 2016-03-16 艾森塔製藥公司 使用布魯頓（Ｂｒｕｔｏｎ）氏酪胺酸激酶（ＢＴＫ）抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
TW201613892A (en) 2014-08-13 2016-04-16 Celgene Avilomics Res Inc Forms and compositions of an ERK inhibitor
EP3689910A3 (en) * 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
WO2016054627A1 (en) * 2014-10-03 2016-04-07 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance
TW201628622A (zh) * 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
ES2843323T3 (es) 2014-12-18 2021-07-16 Principia Biopharma Inc Tratamiento de pénfigo
MX2017008486A (es) * 2014-12-23 2017-09-19 Pharmacyclics Llc Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion.
WO2016106652A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
WO2016123504A1 (en) * 2015-01-30 2016-08-04 Pharmacyclics Llc Btk inhibitor combinations and multidrug-resistance
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
JP6190079B2 (ja) 2015-03-31 2017-08-30 大鵬薬品工業株式会社 ３，５−二置換ベンゼンアルキニル化合物の結晶
CN113546054A (zh) 2015-04-06 2021-10-26 詹森药业有限公司 包含依鲁替尼的组合物
EP3284466A4 (en) 2015-04-13 2018-12-05 Daiichi Sankyo Company, Limited Treatment method combining mdm2 inhibitor and btk inhibitor
CA2986175A1 (en) 2015-05-26 2016-12-01 Morphosys Ag Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
US20180305350A1 (en) * 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
SI3317281T1 (sl) 2015-07-02 2020-08-31 Acerta Pharma B.V. Trdne oblike in formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin -2-il)imidazo(1,5-a)pirazin-1-il)-n-(piridin-2-il)benzamida
MX2018001369A (es) * 2015-07-31 2018-11-29 Pharmacyclics Llc Combinaciones de inhibidores de tirosina quinasa de bruton y sus usos.
US20170209462A1 (en) * 2015-08-31 2017-07-27 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
MA44909A (fr) * 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
KR20180109842A (ko) 2015-09-16 2018-10-08 록쏘 온콜로지, 인코포레이티드 화합물
EP4012415A3 (en) 2015-12-04 2022-12-07 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
CN114605327B (zh) 2015-12-16 2025-03-11 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
AU2017227929B2 (en) 2016-02-29 2022-06-30 F. Hoffmann-La Roche Ag Dosage form compositions comprising an inhibitor of Bruton's tyrosine kinase
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JP7085985B2 (ja) 2016-03-04 2022-06-17 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物
WO2017184774A1 (en) 2016-04-19 2017-10-26 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
CN109600989B (zh) 2016-06-29 2022-11-04 普林斯匹亚生物制药公司 2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁烷-3-基)哌嗪-1-基]戊-2-烯腈的改性的释放制剂
AU2017293423B2 (en) 2016-07-05 2023-05-25 Beone Medicines I Gmbh Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
CN116478165A (zh) 2016-08-16 2023-07-25 百济神州(苏州)生物科技有限公司 一种化合物的晶型、其制备和用途
AU2017313085B2 (en) 2016-08-19 2024-06-20 Beone Medicines I Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
KR20190058550A (ko) 2016-09-19 2019-05-29 메이 파마, 아이엔씨. 병용 요법
JP7590810B2 (ja) 2016-10-06 2024-11-27 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｔｋ阻害剤を調製するための方法および中間体
IL266216B2 (en) 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
MX2019005029A (es) 2016-11-03 2019-10-24 Juno Therapeutics Inc Terapia de combinación de una terapia de células t y un inhibidor de tirosina cinasa de bruton (btk).
WO2018102785A2 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
EP3555092A4 (en) 2016-12-13 2020-05-13 Princeton Drug Discovery Inc PROTEIN KINASE INHIBITORS
CN110248668B (zh) 2016-12-15 2023-05-30 杜克大学 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
EP3631468A1 (en) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
US11413310B2 (en) 2017-06-02 2022-08-16 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
CN110799543A (zh) 2017-06-26 2020-02-14 百济神州有限公司 肝细胞癌的免疫治疗
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
MA50057A (fr) 2017-09-01 2020-07-08 Juno Therapeutics Inc Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire
TW201922256A (zh) * 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
KR102473372B1 (ko) 2018-03-19 2022-12-05 다이호야쿠힌고교 가부시키가이샤 알킬황산나트륨을 포함하는 의약 조성물
MX2020010437A (es) 2018-04-05 2021-01-29 Sumitomo Pharma Oncology Inc Inhibidores de axl cinasa y uso de los mismos.
AU2019252793A1 (en) 2018-04-13 2020-10-15 Sumitomo Pharma America, Inc. PIM kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
MX2020011527A (es) 2018-05-03 2021-02-26 Juno Therapeutics Inc Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa.
KR20250125432A (ko) 2018-06-15 2025-08-21 얀센 파마슈티카 엔브이 이브루티닙을 포함하는 제형/조성물
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
CN109276571A (zh) * 2018-10-31 2019-01-29 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型硝基酞嗪酮btk抑制剂联合用药物组合物及其应用
CN109331005A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和氟酞嗪类btk抑制剂联合用药物组合物及其应用
CN109481441A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109481442A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和邻苯基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109481443A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和邻苯氟酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109481444A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和酞嗪类btk抑制剂联合用药物组合物及其应用
CN109394766A (zh) * 2018-10-31 2019-03-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和对苯硝基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109172562A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109223759A (zh) * 2018-10-31 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109394765A (zh) * 2018-10-31 2019-03-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和对苯基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109288841A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和对苯氟酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109331018A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和硝基酞嗪酮btk抑制剂联合用药物组合物及其应用
MX2021006244A (es) 2018-11-30 2021-09-10 Juno Therapeutics Inc Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva.
EP3886875B1 (en) 2018-11-30 2024-05-08 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
AU2020221247B2 (en) 2019-02-12 2024-12-12 Sumitomo Pharma America, Inc. Formulations comprising heterocyclic protein kinase inhibitors
KR20210131371A (ko) 2019-02-22 2021-11-02 얀센 파마슈티카 엔.브이. 1-(1-옥소-1,2-디하이드로이소퀴놀린-5-일)-5-(트리플루오로메틸)-n-(2-(트리플루오로메틸)피리딘-4-일)-1h-피라졸-4-카복사미드 일수화물의 결정질 형태
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
KR20210151880A (ko) 2019-04-11 2021-12-14 얀센 파마슈티카 엔.브이. Malt1 억제제로서의 피리딘 고리 함유 유도체
CN113939289A (zh) 2019-06-10 2022-01-14 百济神州瑞士有限责任公司 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
US20220298578A1 (en) * 2019-06-25 2022-09-22 Université de Paris Detection of relb activation for predicting a prognostic in b-cell lymphoma
CN110724143B (zh) * 2019-10-09 2021-03-23 清华大学 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用
KR20220080179A (ko) 2019-10-14 2022-06-14 프린시피아 바이오파마, 인코퍼레이티드 (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을 투여하여 면역 혈소판 감소증을 치료하는 방법
JP7581345B2 (ja) * 2019-10-21 2024-11-12 セルジーン コーポレーション ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを用いて慢性リンパ性白血病を治療する方法
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN115398231A (zh) 2019-12-06 2022-11-25 朱诺治疗学股份有限公司 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法
KR20220130184A (ko) 2020-01-22 2022-09-26 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1H-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 결정질 형태
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11433072B1 (en) 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
WO2023014817A1 (en) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
CN120302975A (zh) 2022-10-31 2025-07-11 住友制药美国公司 治疗骨髓增生性肿瘤的pim1抑制剂
DE202023107671U1 (de) 2023-12-27 2024-01-31 Aglave Hanmant Raghunath Umweltfreundliches System zur Vorbeugung und Bekämpfung von bodenbürtigen Krankheiten bei Sojabohnen durch Präzisionslandwirtschaft
CN119040247B (zh) * 2024-10-30 2025-02-18 北京三元食品股份有限公司 乳酸多韦替尼在上调细胞中乳铁蛋白表达中的应用

Family Cites Families (351)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547119A (en) 1967-12-08 1970-12-15 Baxter Laboratories Inc Catheter assembly
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4311137A (en) 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4531937A (en) 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US4755173A (en) 1986-02-25 1988-07-05 Pacesetter Infusion, Ltd. Soft cannula subcutaneous injection set
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
JPH01167840A (ja) 1987-12-24 1989-07-03 Konica Corp 新規な写真用シアンカプラー
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
CA2108575C (en) 1991-04-16 2002-10-22 Kouichi Nakamichi Method of manufacturing solid dispersion
EP0773227A1 (en) 1991-09-18 1997-05-14 Affymax Technologies N.V. Diverse collections of oligomers in use to prepare drugs, diagnostic reagents, pesticides or herbicides
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
ES2149781T3 (es) 1991-11-22 2000-11-16 Procter & Gamble Pharma Composiciones de risedronato de liberacion retardada.
ATE293011T1 (de) 1991-11-22 2005-04-15 Affymetrix Inc A Delaware Corp Kombinatorische strategien für die polymersynthese
AU3482493A (en) 1992-01-22 1993-09-01 New England Deaconess Hospital Novel protein tyrosine kinases
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE69332291T2 (de) 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
CA2605872A1 (en) 1992-12-29 1994-06-30 Abbott Laboratories Intermediates for retroviral protease inhibiting compounds
US5545143A (en) 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5530012A (en) 1994-12-22 1996-06-25 Bristol-Myers Squibb Co. 3-alkoxybenzylpiperidine derivatives as melatonergic agents
US5643207A (en) 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
EP0827402A2 (en) 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
EP1240899A3 (en) 1996-01-23 2004-05-19 Ribapharm, Inc. Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
HUP0004421A3 (en) 1996-04-23 2002-10-28 Vertex Pharmaceuticals Inc Cam Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
US5820589A (en) 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
EP1302474A1 (en) 1996-10-16 2003-04-16 Ribapharm, Inc. Monocyclic L-nucleosides, analogs and uses thereof
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6893636B2 (en) 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
PT966465E (pt) 1997-03-14 2003-11-28 Vertex Pharma Inibidores do enzima imfdh
EP0970084B1 (en) 1997-03-19 2003-06-04 Basf Aktiengesellschaft Pyrrolo 2,3d]pyrimidines and their use as tyrosine kinase inhibitors
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US6033860A (en) 1997-10-31 2000-03-07 Affymetrix, Inc. Expression profiles in adult and fetal organs
GB2332325A (en) 1997-12-10 1999-06-16 Snell & Wilcox Ltd Video signal spatial interpolation for de-interlacing processing
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
JP2002512216A (ja) 1998-04-17 2002-04-23 パーカー ヒューズ インスティテュート Ｂｔｋインヒビターならびにその同定方法および使用方法
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
WO2000019209A1 (en) 1998-09-28 2000-04-06 Diacrin, Inc. Determining resistance to treatment for hepatitis c virus
AT411956B (de) 1998-10-01 2004-08-26 Masterfoods Austria Ohg Verfahren zur herstellung eines waffelproduktes, anlage zur durchführung dieses verfahrens und nach diesem verfahren hergestelltes waffelprodukt
US6824768B2 (en) 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
US6198966B1 (en) 1999-02-26 2001-03-06 Medtronic, Inc. Recirculating implantable drug delivery system
AR029341A1 (es) 1999-03-19 2003-06-25 Vertex Pharma Inhibidores de la enzima impdh (inosina-5'-monofosfato dehidrogenasa)
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
JP2002542202A (ja) 1999-04-19 2002-12-10 シェリング・コーポレーション 抗酸化剤を伴ったリバビリンを含有するｈｃｖ組み合わせ治療薬
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP2003509428A (ja) 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療薬としてのピラゾロピリミジン
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
DE60014130T2 (de) 1999-10-06 2006-03-09 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
WO2001032210A2 (en) 1999-10-29 2001-05-10 Pharmacyclics, Inc. Compositions for treating atheroma and neoplastic tissue
JP2003516351A (ja) 1999-11-30 2003-05-13 パーカー ヒューズ インスティテュート コラーゲン誘導血小板凝集阻害剤
EP1246829A1 (en) 1999-12-17 2002-10-09 Ariad Pharmaceuticals, Inc. Novel heterocycles
US7835970B1 (en) 2000-02-02 2010-11-16 Cmvt, Llc Method and system for automated auction and tender of complex multi-variable commodities
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
US20020004584A1 (en) 2000-03-09 2002-01-10 Laughlin Mark A. HIV immune adjuvant therapy
EP1268856A2 (de) 2000-04-07 2003-01-02 Epigenomics AG Detektion von snp's und cytosin-methylierungen
US6673333B1 (en) 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
AU2001283224B2 (en) 2000-08-09 2007-06-28 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
CA2425522A1 (en) 2000-10-18 2002-04-25 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
WO2002038797A2 (en) 2000-10-23 2002-05-16 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase, their identification and use
JP3889708B2 (ja) 2000-11-20 2007-03-07 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎トリペプチド阻害剤
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
WO2002045684A2 (en) 2000-12-06 2002-06-13 Pharmacia Corporation Rapidly dispersing pharmaceutical composition comprising effervescent agents
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
US20030114467A1 (en) 2001-06-21 2003-06-19 Shakespeare William C. Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
GB0116249D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods
US20040248906A1 (en) 2001-08-10 2004-12-09 Donato Nicholas J Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia
US20030118078A1 (en) 2001-08-10 2003-06-26 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
IL161409A0 (en) 2001-11-21 2004-09-27 Sunesis Pharmaceuticals Inc Methods for ligand discovery
US20030175761A1 (en) 2001-12-07 2003-09-18 Sabath Daniel E. Identification of genes whose expression patterns distinguish benign lymphoid tissue and mantle cell, follicular, and small lymphocytic lymphoma
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
CA2413475C (en) 2002-04-25 2010-07-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll)
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
ZA200500480B (en) 2002-07-15 2006-10-25 Wyeth Corp Methods and compositions for modulating T helper (TH) cell development and function
BR0313059B8 (pt) 2002-07-29 2021-07-27 Rigel Pharmaceuticals composto, e, composição farmacêutica
CA2494942A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
WO2004060319A2 (en) 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7687506B2 (en) 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
WO2004100868A2 (en) 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
US20070032457A1 (en) 2003-05-16 2007-02-08 Blatt Lawrence M Combination therapy for cancer treatment
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US6950493B2 (en) 2003-06-25 2005-09-27 Besson Guy M Dynamic multi-spectral CT imaging
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
EP1664762A4 (en) 2003-09-03 2008-08-13 Us Gov Health & Human Serv METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
JP2005089352A (ja) 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
CN102139105A (zh) 2003-09-30 2011-08-03 特莱索恩儿童健康研究院 免疫治疗方法
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
SG132683A1 (en) 2003-10-15 2007-06-28 Osi Pharm Inc Imidazopyrazine tyrosine kinase inhibitors
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
US20050153990A1 (en) 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
US20070281907A1 (en) 2003-12-22 2007-12-06 Watkins William J Kinase Inhibitor Phosphonate Conjugates
ES2298861T3 (es) 2004-01-08 2008-05-16 Wyeth Composicion farmaceutica que puede obtenerse mediante compresion directa para la administracion oral de cci-779.
AU2005228845A1 (en) 2004-01-26 2005-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
WO2005074603A2 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
EP1763345A2 (en) 2004-06-18 2007-03-21 GPC Biotech Inc. Kinase inhibitors for treating cancers
ITMI20041314A1 (it) 2004-06-30 2004-09-30 Nuvera Fuel Cells Europ Srl Dispositivo di raffreddamento per celle a combustibili a membrana
CN101001647A (zh) 2004-07-08 2007-07-18 塞勒克塔有限公司 使用放射性标记的磷脂醚类似物的虚拟结肠镜检查
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
WO2006036726A1 (en) 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
WO2006036941A2 (en) 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Specific kinase inhibitors
BRPI0516166A (pt) 2004-09-28 2008-08-26 Janssen Pharmaceutica Nv antagonista do ccr2 de dipiperidina substituìda
MX2007003533A (es) 2004-10-01 2007-05-23 Medarex Inc Metodos de tratar linfomas cd30 positivas.
KR20070119606A (ko) 2004-11-10 2007-12-20 씨지아이 파마슈티칼스, 인크. 특정 이미다조[１,２-ａ]피라진-８-일아민, 그의 제조 방법및 용도
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
MX2007009317A (es) 2005-02-03 2008-01-30 Gen Hospital Corp Metodo para tratar cancer resistente a gefitinib.
WO2006099075A2 (en) 2005-03-10 2006-09-21 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
AU2006227880A1 (en) 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer
US7599542B2 (en) 2005-04-08 2009-10-06 John Philip Brockway System and method for detection and display of diseases and abnormalities using confidence imaging
CA2606147C (en) 2005-05-12 2011-07-05 Abbott Laboratories Apoptosis promoters
RU2411242C2 (ru) 2005-05-13 2011-02-10 Айрм, Ллк. Соединения и композиции в качестве ингибиторов протеинкиназ
CN102603581B (zh) 2005-06-22 2015-06-24 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US20070065449A1 (en) 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
AU2006310340B2 (en) 2005-11-04 2011-02-10 Novartis Ag Changing TH1/TH2 balance in split influenza vaccines with adjuvants
EP1957491A2 (en) 2005-11-12 2008-08-20 Boehringer Ingelheim International GmbH Pyrrolo (2,3-b) pyridine derivatives useful as tec kinase inhibitors
WO2007059329A2 (en) 2005-11-16 2007-05-24 Pharmacyclics, Inc. Methods and compositions for treating cancer
CN101395147B (zh) 2005-12-28 2013-05-29 弗特克斯药品有限公司 作为atp-结合盒转运蛋白调节剂用于治疗囊性纤维化的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物及相关化合物
BRPI0621027A2 (pt) 2006-01-13 2011-11-29 Pharmacyclics Inc composto, composição farmacêutica
WO2007089911A2 (en) * 2006-01-30 2007-08-09 The Scripps Research Institute Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
GB0605521D0 (en) 2006-03-18 2006-04-26 Isis Innovation Adjuvant
GB2453058A (en) 2006-04-04 2009-03-25 Univ California Kinase antagonists
KR20140019032A (ko) 2006-04-05 2014-02-13 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
CN101415426A (zh) 2006-04-07 2009-04-22 诺瓦提斯公司 c-Src抑制剂与嘧啶基氨基苯甲酰胺类化合物的组合治疗白血病的用途
AU2007254179B2 (en) 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
KR20090057035A (ko) 2006-08-21 2009-06-03 유나이티드 세러퓨틱스 코오포레이션 바이러스 감염의 치료를 위한 병용 요법
US20220213106A1 (en) 2006-09-22 2022-07-07 Pharmacyclics Llc Inhibitors of Bruton's Tyrosine Kinase
ES2616789T3 (es) 2006-09-22 2017-06-14 Pharmacyclics, Inc. Inhibidores de tirosina cinasa de Bruton
EP2083852B1 (en) 2006-10-04 2014-12-10 Dana-Farber Cancer Institute, Inc. Tumor immunity
EP2089391B1 (en) 2006-11-03 2013-01-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
EP2092075A2 (en) 2006-11-06 2009-08-26 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
KR20120090100A (ko) 2006-12-26 2012-08-16 파마시클릭스, 인코포레이티드 병용 치료에 있어서 히스톤 디아세틸라제 억제제 이용 및 생체표지 감시 방법
EP2120900A2 (en) 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
EP2546651A1 (en) 2007-03-14 2013-01-16 Bionsil S.r.l. Modulator compounds of the drug resistance in epithelial tumour cells
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
ES2562215T3 (es) * 2007-03-28 2016-03-03 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
AU2008236634A1 (en) 2007-04-05 2008-10-16 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20090010911A1 (en) 2007-04-06 2009-01-08 Iowa State University Research Foundation, Inc. Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
WO2008127659A2 (en) 2007-04-13 2008-10-23 University Of Texas Southwestern Medical Center Combination therapy for cancer
TWI362930B (en) 2007-04-27 2012-05-01 Purdue Pharma Lp Trpv1 antagonists and uses thereof
WO2008138578A2 (en) 2007-05-11 2008-11-20 Medical Prognosis Institute Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2009021137A2 (en) 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
JP5376780B2 (ja) 2007-08-08 2013-12-25 株式会社東芝 圧電モータおよびカメラ装置
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2214486A4 (en) 2007-10-19 2011-03-09 Avila Therapeutics Inc HETEROARYL COMPOUNDS AND ITS USES
ES2444144T3 (es) * 2007-10-23 2014-02-24 F. Hoffmann-La Roche Ag Nuevos inhibidores de quinasa
PT2220116E (pt) 2007-11-12 2012-12-07 Theraclone Sciences Inc Composições e métodos para a terapia e o diagnóstico da gripe
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CN101475632B (zh) 2008-01-03 2012-01-04 张喜田 具有抗肿瘤作用的重组灵芝免疫调节蛋白及其药物制剂
WO2009089399A2 (en) 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
TWI500624B (zh) 2008-03-25 2015-09-21 Hoffmann La Roche 具有增進之抗體依賴型細胞毒性之第ii型抗－ｃｄ２０抗體之組合療法
GB0805356D0 (en) 2008-03-25 2008-04-30 Isis Innovation Vaccine adjuvant composition
WO2009140853A1 (en) 2008-05-23 2009-11-26 The University Of Hong Kong Combination therapy for the treatment of influenza
WO2009149179A2 (en) 2008-06-03 2009-12-10 Aethlon Medical Inc. Enhanced antiviral therapy methods and devices
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
JP2012504553A (ja) 2008-07-29 2012-02-23 フロンティア サイエンティフィック インコーポレイテッド 微生物の殺滅または増殖抑制のためのテトラキス（ｎ−アルキルピリジニウム）−ポルフィリン誘導体の使用
EP2352827A4 (en) 2008-09-05 2016-07-20 Celgene Avilomics Res Inc ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS
WO2010034670A2 (en) 2008-09-26 2010-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Host cell kinases as targets for antiviral therapies against hcv infection
EP2355828B1 (en) 2008-11-13 2018-05-30 Gilead Calistoga LLC Therapies for hematologic malignancies
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
CN103497192B (zh) 2008-12-09 2015-09-23 吉里德科学公司 Toll样受体调节剂
JP2012512157A (ja) 2008-12-15 2012-05-31 イーライ リリー アンド カンパニー 癌を治療するためのエンザスタウリン
JP2012512636A (ja) 2008-12-18 2012-06-07 エフ．ホフマン−ラ ロシュ アーゲー Ｈｃｖ処置応答についてのバイオマーカー
EP2396028A2 (en) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
BRPI1006438A2 (pt) 2009-04-20 2016-09-27 Genentech Inc terapia adjuvante de cancer
JP5656976B2 (ja) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
PL2435432T6 (pl) 2009-05-26 2024-02-12 Abbvie Ireland Unlimited Company Środki wywołujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych
LU91583B1 (en) 2009-07-03 2011-01-04 Wurth Paul Sa Sealing valve arrangement for a shaft furnace charging installation
IN2012DN02534A (enExample) 2009-09-16 2015-08-28 Avila Therapeutics Inc
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
US8299070B2 (en) 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
PL2509602T3 (pl) 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
US9371567B2 (en) 2010-04-19 2016-06-21 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of BTK inhibitors
EP2571878B1 (en) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
CA2799944A1 (en) 2010-05-20 2011-11-24 University Of Rochester Methods and compositions related to modulating autophagy
KR101537148B1 (ko) 2010-05-31 2015-07-15 오노 야꾸힝 고교 가부시키가이샤 푸리논 유도체
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US8957065B2 (en) 2010-06-23 2015-02-17 Hanmi Science Co., Ltd Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
GB2481611A (en) 2010-06-30 2012-01-04 Statoil Asa Test cell for well fluid assessment
RU2013109393A (ru) 2010-08-10 2014-09-20 Сэлджин Авиаломикс Ресеарч, Инк. Безилатная соль ингибитора втк
UY33746A (es) 2010-11-23 2012-06-29 Abbott Lab Método de tratamiento que usa inhibidores selectivos de bcl-2
CA2820709C (en) 2011-02-28 2016-02-16 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
CN103534258B (zh) 2011-05-17 2016-09-14 普林斯匹亚生物制药公司 酪氨酸激酶抑制剂
CN103765212A (zh) 2011-06-27 2014-04-30 杰克逊实验室 治疗癌症和自体免疫性疾病的方法和组合物
SI3689878T1 (sl) 2011-07-19 2021-12-31 Merck Sharp & Dohme B.V. 4-imidazopiridazin-1-il-benzamidi in 4-imidazotriazin-1-il-benzamidi kot Btk-zaviralci
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013036994A1 (en) 2011-09-16 2013-03-21 Biota Scientific Management Pty Ltd Compounds for the treatment of hcv
US8580958B1 (en) 2011-09-22 2013-11-12 The United States Of America As Represented By The Secretary Of The Air Force Two-photon absorbing polyhydroxy diphenylamino-dialkylfluorene-1,3,5-triazine molecules
JP6506555B2 (ja) 2011-10-19 2019-04-24 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用
US8669251B2 (en) 2011-11-03 2014-03-11 Genentech, Inc. 8-fluorophthalazin-1(2H)-one compounds
EP2788020A4 (en) 2011-12-05 2015-04-29 Immunomedics Inc THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
HK1209632A1 (en) 2012-01-10 2016-04-08 林伯士艾瑞斯公司 Irak inhibitors and uses thereof
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US20150072988A1 (en) 2012-03-30 2015-03-12 The Johns Hopkins University Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
GB201207305D0 (en) 2012-04-26 2012-06-13 E Therapeutics Plc Therapy
JP5514256B2 (ja) 2012-05-18 2014-06-04 株式会社東芝 磁気記憶素子及びその製造方法
KR20230170108A (ko) 2012-06-04 2023-12-18 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
AU2013289204B2 (en) 2012-07-10 2018-05-10 The Regents Of The University Of California Methods of inducing anesthesia
US8684552B2 (en) 2012-07-11 2014-04-01 Agio International Company, Ltd Lighted furniture assembly
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
JP6408993B2 (ja) 2012-09-07 2018-10-17 ジェネンテック， インコーポレイテッド タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法
WO2014071205A1 (en) 2012-11-02 2014-05-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies
CA2890111A1 (en) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
BR112015011171A2 (pt) 2012-11-15 2017-07-11 Pharmacyclics Inc compostos de pirrolopirimidina como inibidores da quinase
BR112015014034A2 (pt) 2013-01-10 2017-07-11 Nimbus Iris Inc inibidores de irak e usos dos mesmos
EP2948458B1 (en) 2013-01-23 2019-05-01 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014124227A1 (en) 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2902099C (en) 2013-03-08 2020-06-02 F. Hoffmann-La Roche Ag Egfr mutation blood testing
JP2016512549A (ja) 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
MX369503B (es) 2013-04-08 2019-11-11 Pharmacyclics Llc Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
EP3003309B1 (en) 2013-05-30 2020-09-09 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
AP2015008888A0 (en) 2013-06-07 2015-11-30 Rhizen Pharmaceuticals Sa Dual selective pi3 delta and gamma kinase inhibitors
EP3024456A4 (en) 2013-07-26 2017-04-12 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
CA2920534A1 (en) 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
EA201690618A1 (ru) 2013-09-30 2016-09-30 Фармасайкликс Элэлси Ингибиторы тирозинкиназы брутона
US20150105409A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating nonhodgkin's lymphoma
JP2016538270A (ja) 2013-10-25 2016-12-08 ファーマサイクリックス エルエルシー 移植片対宿主病を処置し予防する方法
EP3060251A4 (en) 2013-10-25 2017-12-06 Pharmacyclics LLC Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
US20150140036A1 (en) 2013-11-13 2015-05-21 Novartis Institutes For Biomedical Research, Inc. Low, immune enhancing, dose mtor inhibitors and uses thereof
US10314842B2 (en) 2013-12-02 2019-06-11 Cornell University Methods for treating B cell proliferative disorders
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN105949197A (zh) 2014-01-29 2016-09-21 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法
WO2015127234A1 (en) 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
US20150238490A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
WO2015149105A1 (en) 2014-04-04 2015-10-08 Bionomics Limited Method for treating chronic lymphocytic leukemia
US9815842B2 (en) 2014-05-28 2017-11-14 Novartis Ag Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors
US20150361504A1 (en) 2014-06-13 2015-12-17 Pharmacyclics Llc Biomarker for predicting response of cll to treatment with a btk inhibitor
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016014859A1 (en) 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
BR112017001677A2 (pt) 2014-08-01 2018-07-17 Pharmacyclics Llc biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk
CA2955747A1 (en) 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
BR112017002232A2 (pt) 2014-08-08 2018-07-24 Janssen Pharmaceutica Nv combinações de inibidor de tirosina quinase de bruton e usos das mesmas
WO2016024227A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
KR20190125537A (ko) 2014-09-16 2019-11-06 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체 조정제의 고체 형태
WO2016044774A1 (en) 2014-09-18 2016-03-24 Pharmacyclics Llc Dendritic cell based vaccine with bruton's tyrosine kinase inhibitor
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
WO2016054627A1 (en) 2014-10-03 2016-04-07 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance
EP4029508A1 (en) 2014-10-10 2022-07-20 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonists and checkpoint inhibitors
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
TW201628622A (zh) 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
MX2017008486A (es) 2014-12-23 2017-09-19 Pharmacyclics Llc Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion.
WO2016123504A1 (en) 2015-01-30 2016-08-04 Pharmacyclics Llc Btk inhibitor combinations and multidrug-resistance
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
PH12021551982A1 (en) 2015-03-04 2022-09-05 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
WO2016161347A1 (en) 2015-04-03 2016-10-06 Pharmacyclics Llc Combinations for generating tumor-specific immunological memory
CN106336413B (zh) 2015-07-09 2021-04-20 广东东阳光药业有限公司 作为jak抑制剂的化合物及其用途
WO2017011314A1 (en) 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
CN106474143A (zh) 2015-08-26 2017-03-08 长春华普生物技术有限公司 Toll样受体TLR7和TLR9抑制性寡核苷酸在制备用于治疗B细胞淋巴瘤的药物方面的应用
US20170209462A1 (en) 2015-08-31 2017-07-27 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
US20170071962A1 (en) 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
WO2017087947A2 (en) 2015-11-19 2017-05-26 Pharmacyclics Llc Method of treatment of follicular lymphoma with a btk inhibitor

Also Published As

Publication number Publication date
CA3154024C (en) 2024-02-27
US9814721B2 (en) 2017-11-14
JP7042950B2 (ja) 2022-03-28
JP2022088408A (ja) 2022-06-14
PH12016501206A1 (en) 2018-02-12
ZA201209381B (en) 2014-05-28
US20220249494A1 (en) 2022-08-11
CA3007787A1 (en) 2011-12-08
MY191929A (en) 2022-07-18
NZ702485A (en) 2016-04-29
JP2021155426A (ja) 2021-10-07
US20120183535A1 (en) 2012-07-19
MX342405B (es) 2016-09-28
SG10201809111XA (en) 2018-11-29
EA201270793A2 (ru) 2013-08-30
US20150031711A1 (en) 2015-01-29
US20130310402A1 (en) 2013-11-21
CA3022256C (en) 2021-03-30
CA3022256A1 (en) 2011-12-08
US20200163968A1 (en) 2020-05-28
CA3007787C (en) 2020-03-10
MX380504B (es) 2025-03-12
US20180036313A1 (en) 2018-02-08
US20180256581A1 (en) 2018-09-13
WO2011153514A9 (en) 2012-04-05
US20180015091A1 (en) 2018-01-18
BR112012030625A2 (pt) 2017-06-27
MX2020004438A (es) 2021-03-25
NZ717373A (en) 2017-11-24
NZ772688A (en) 2022-09-30
CA3154024A1 (en) 2011-12-08
US10004746B2 (en) 2018-06-26
US11672803B2 (en) 2023-06-13
US20140194446A1 (en) 2014-07-10
US20190358234A1 (en) 2019-11-28
JP6376416B2 (ja) 2018-08-22
US10016435B2 (en) 2018-07-10
PH12021550758A1 (en) 2022-02-21
NZ736048A (en) 2019-09-27
CN103153311A (zh) 2013-06-12
MX387728B (es) 2025-03-18
JP6580760B2 (ja) 2019-09-25
US10004745B2 (en) 2018-06-26
EA201270793A8 (ru) 2019-01-31
JP2024028806A (ja) 2024-03-05
KR101580714B1 (ko) 2016-01-04
IL223181B (en) 2020-10-29
NZ755485A (en) 2021-04-30
EP2575818A2 (en) 2013-04-10
EA201890869A2 (ru) 2018-09-28
JP5841998B2 (ja) 2016-01-13
US20150031710A1 (en) 2015-01-29
CA2800913A1 (en) 2011-12-08
US20160175312A1 (en) 2016-06-23
MX380899B (es) 2025-03-12
EA031737B1 (ru) 2019-02-28
JP2016065078A (ja) 2016-04-28
US9801881B2 (en) 2017-10-31
CA3240281A1 (en) 2011-12-08
CL2012003381A1 (es) 2013-03-22
JP2020063231A (ja) 2020-04-23
US8754090B2 (en) 2014-06-17
EA201890869A3 (ru) 2019-03-29
CN107898791A (zh) 2018-04-13
US10478439B2 (en) 2019-11-19
US20120100138A1 (en) 2012-04-26
US20230248730A1 (en) 2023-08-10
PH12012502356A1 (en) 2013-02-11
JP2013527249A (ja) 2013-06-27
US20160324859A1 (en) 2016-11-10
US20130273030A1 (en) 2013-10-17
CA3113343C (en) 2024-10-08
US20170035762A1 (en) 2017-02-09
US20210169885A1 (en) 2021-06-10
US20130195852A1 (en) 2013-08-01
US9125889B2 (en) 2015-09-08
US20130202611A1 (en) 2013-08-08
JP6057309B2 (ja) 2017-01-11
US20180280395A1 (en) 2018-10-04
JP2018197238A (ja) 2018-12-13
CA2800913C (en) 2019-07-23
CA3113343A1 (en) 2011-12-08
MX2012014049A (es) 2013-03-12
IL275459A (en) 2020-08-31
US10751342B2 (en) 2020-08-25
SG186077A1 (en) 2013-01-30
PH12016501206B1 (en) 2018-02-12
IL223181A0 (en) 2013-02-03
US10653696B2 (en) 2020-05-19
NZ753024A (en) 2020-08-28
KR20130086957A (ko) 2013-08-05
MX2020004501A (es) 2021-11-09
NZ604040A (en) 2015-02-27
AU2011261185A1 (en) 2013-01-10
CA3007788A1 (en) 2011-12-08
US20120087915A1 (en) 2012-04-12
EP2575818A4 (en) 2013-11-06
US20220175785A1 (en) 2022-06-09
US8999999B2 (en) 2015-04-07
JP2017039767A (ja) 2017-02-23
US20230293532A1 (en) 2023-09-21
IL300955A (en) 2023-04-01
CA3007788C (en) 2020-03-10
WO2011153514A2 (en) 2011-12-08
US9801883B2 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
NZ789041A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
ZA202502152B (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
MX2021015408A (es) Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton.
MX2009006613A (es) Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
PL2324008T3 (pl) 3,4-diarylopirazole jako inhibitory kinazy białkowej
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
HK1249736A1 (zh) 布鲁顿氏酪氨酸激酶抑制剂的共结晶体
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
HK1249737A1 (zh) 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式
WO2012145575A3 (en) Therapy for leukemia
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
JP2012041314A5 (enExample)
RU2007122391A (ru) S-миртазапин для лечения приливов
MX2008015323A (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion.
WO2009006565A3 (en) Formulations and methods for inhibiting anaerobes, gram negative bacteria, protozoa and other microbial growth with morinda citrifolia l. enhanced formulations
TR200704897A1 (tr) Uzatılmış salım sağlayan gliklazid formülasyonları@
TW202600141A (zh) 布魯東氏(bruton’s)酪胺酸激酶抑制劑之醫藥調配物
TR201818886T4 (tr) Bir ilave antidiyabetik ajanla kombine edilmiş dpp-ıv inhibitörü, bu formülasyonları içeren tabletler, bunların kullanımları ve bunları hazırlama prosesi.
UA38335U (ru) Способ лечения рецидивного кандидозного вульвовагинита
UA38444U (ru) Мазь для лечения воспалительных заболеваний суставов и мышц

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 03 JUN 2024 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20240205

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2025 BY THOMSON REUTERS

Effective date: 20240502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2026 BY THOMSON REUTERS

Effective date: 20250501